Block Listing Six Monthly Return

RNS Number : 8182Q

Alliance Pharma PLC

30 June 2022

 

For immediate release

30 June 2022

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)  The Alliance Pharma plc Approved Share Option Plan 2005 b)  The Alliance Pharma plc Share Option Plan 2006 c)  The Alliance Pharma plc Company Share Option Plan 2015 d)  The Alliance Pharma plc Long-Term Incentive Plan 2019
Period of return:	From:	28 December 2021	To:	28 June 2022
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)  18,618 b)  3,091,781 c)  10,399,643 d)  Nil
Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)  167,351 b)  Nil c)  Nil d)  1,500,000
Less:   Number of securities issued/allotted under schemes during period:		a)  24,023 b) 540,613 c)  745,623 d) Nil
Equals:   Balance under schemes not yet issued/allotted at end of period:		e)  161,946 f)  2,551,168 g)  9,654,020 h)  1,500,000

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
[e-mail]
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website :  www.alliancepharmaceuticals.com

 

END

 

 

BLRURAKRUAUNORR